ANXA2 is a Potential Biomarker Associated with Poor Prognosis in Glioma

ANXA2, a calcium-dependent phospholipid-binding protein, regulates critical physiological processes such as membrane trafficking, signal transduction, and cell adhesion. While accumulating evidence implicates ANXA2 in tumor progression across multiple malignancies, its functional and prognostic significance in glioma remains poorly defined. In this study, we utilized The Cancer Genome Atlas (TCGA), the Genotypic Tissue Expression (GTEx) database, and the Chinese Glioma Genome Atlas (CGGA) to investigate the associations between ANXA2 and clinicopathological and molecular features of glioma patients, as well as the correlation of patient prognosis. Our study showed that high expression of ANXA2 was significantly associated with poor patient prognosis. Further analysis of the biological role of ANXA2 in gliomas revealed that ANXA2 is involved in a variety of biological processes involved in glioma development, including immune responses, cellular activation, and modulation of immune system defenses. Immuno-infiltration analysis of the TIMER database revealed a correlation between high ANXA2 expression and infiltration of various immune cells as well as immune checkpoints in glioma. In summary, ANXA2 represents a promising potential biomarker for clinical diagnosis and therapeutic targeting in glioma.